Azulfidine En-tabs

Hepatic or renal dysfunction or blood dyscrasias: usually not recommended. Discontinue if renal function deteriorates while on therapy, toxic or hypersensitivity reactions occur, or if EN-tabs passed undisintegrated. Discontinue at the 1^st signs/symptoms of severe cutaneous adverse reactions. Monitor for signs/symptoms of infection before and after therapy; discontinue if serious infection develops. History of recurring or chronic infections. Underlying conditions or concomitant drugs which may predispose to infections. Severe allergy. Asthma. G6PD deficiency. Monitor CBCs, differential WBC, LFTs before starting, every other week for 1^st 3 months, then once monthly for next 3 months, then once every 3 months; urinalysis, renal function, and serum sulfapyridine periodically; discontinue while awaiting blood test results. Maintain adequate hydration. Continue medication after symptoms controlled. See full labeling for desensitizing regimen. Elderly. Pregnancy. Nursing mothers: monitor infants.

Hepatic or renal dysfunction or blood dyscrasias: usually not recommended. Discontinue if renal function deteriorates while on therapy, toxic or hypersensitivity reactions occur, or if EN-tabs passed undisintegrated. Discontinue at the 1^st signs/symptoms of severe cutaneous adverse reactions. Monitor for signs/symptoms of infection before and after therapy; discontinue if serious infection develops. History of recurring or chronic infections. Underlying conditions or concomitant drugs which may predispose to infections. Severe allergy. Asthma. G6PD deficiency. Monitor CBCs, differential WBC, LFTs before starting, every other week for 1^st 3 months, then once monthly for next 3 months, then once every 3 months; urinalysis, renal function, and serum sulfapyridine periodically; discontinue while awaiting blood test results. Maintain adequate hydration. Continue medication after symptoms controlled. See full labeling for desensitizing regimen. Elderly. Pregnancy. Nursing mothers: monitor infants.